Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center.

Vinay, Keshavamurthy; Cazzaniga, Simone; Amber, Kyle T; Feldmeyer, Laurence; Borradori, Luca (2018). Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center. Journal of the American Academy of Dermatology, 78(4), pp. 806-808. Elsevier 10.1016/j.jaad.2017.11.024

[img]
Preview
Text
1-s2.0-S0190962217326890-main.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (200kB) | Preview

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Cazzaniga, Simone; Feldmeyer, Laurence and Borradori, Luca

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0190-9622

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

05 Mar 2018 15:14

Last Modified:

14 Nov 2018 02:30

Publisher DOI:

10.1016/j.jaad.2017.11.024

PubMed ID:

29146127

Uncontrolled Keywords:

Complete remission First line Pemphigus Relapse Rituximab

BORIS DOI:

10.7892/boris.110145

URI:

https://boris.unibe.ch/id/eprint/110145

Actions (login required)

Edit item Edit item
Provide Feedback